Lung Cancer: New Directions in Senior Patients Assessment.
Anca Iuliana PîslaruSabinne-Marie AlbișteanuAdina Carmen IlieRamona ȘtefaniuAurelia MârzaȘtefan MoscaliucMălina NicoarăAna-Maria TurcuGabriela GrigorașIoana Dana AlexaPublished in: Geriatrics (Basel, Switzerland) (2024)
Age is but one significant prognostic factor in lung cancer, influencing survival, treatment response, and outcomes. This narrative review synthesizes findings from searches of 11 leading databases of research studies, systematic reviews, book chapters, and clinical trial reports on lung cancer in senior patients, with a focus on geriatric assessment as well as biomarkers. Key prognostic factors for lung cancer in seniors include biological age, functional capability, physical and psychological comorbidities, frailty, nutrition, status, and biomarkers like DNA methylation age. We identified the most valuable assessments that balance efficacy with quality of life. Optimizing care and improving outcomes with senior lung cancer patients benefits from a tailored therapeutic approach incorporating a complex geriatric assessment. A multidisciplinary collaboration between geriatricians, oncologists, and pulmonologists is crucial.
Keyphrases
- prognostic factors
- clinical trial
- dna methylation
- healthcare
- palliative care
- end stage renal disease
- emergency department
- ejection fraction
- chronic kidney disease
- open label
- metabolic syndrome
- chronic pain
- randomized controlled trial
- pain management
- deep learning
- insulin resistance
- advanced cancer
- skeletal muscle
- glycemic control
- adverse drug